Neuroblastoma

Title: COG ANBL0532: Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma.

Purpose: To improve the 3-year event free survival (EFS) rate of high-risk neuroblastoma patients through treatment with a tandem consolidation of Thiotepa/Cyclophosphamide followed by Carboplatin/Etoposide/Melphalan (CEM) as compared to single CEM consolidation. To improve the rate of end-induction complete response and very good partial response, compared to historical controls, by use of a topotecan-containing induction regimen. To improve the 3-year local control rate, compared to historical controls, by increasing the local dose of radiation to the residual primary tumor for patients with less than a gross total resection.

Eligibility: Patients must be less than or equal to 30 years of age at the time of initial diagnosis of neuroblastoma or ganglioneuroblastoma which has been verified by histology or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites.

Principal Investigator: Wiley, Joseph M.

Phase: III

For more information, contact: Entrup, Stephanie

Telephone Number: 410-601-8393

Email sentrup@lifebridgehealth.org

Approved Enrollment Number: 5

Current Enrollment: 0
Neuroblastoma

**Title:** Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue. (COG ANBL0032)

**Purpose:** To compare two different treatments aimed at maintaining or improving patients' response to treatment on A3973.

**Eligibility:** All patients must be diagnosed with neuroblastoma, and categorized as high risk at the time of diagnosis and must be less than or equal to 30.99 years of age at diagnosis. All patients must have completed therapy including intensive induction followed by ASCT and radiotherapy to be eligible for the study.

**Principal Investigator:** Wiley, Joseph M.

**Phase:** III

**For more information, contact:** Entrup, Stephanie

**Telephone Number:** 410-601-8393

**Email** sentrup@lifebridgehealth.org

**Approved Enrollment Number:** 5

**Current Enrollment:** 1
Neuroblastoma

**Title:** A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated with Chemotherapy and Prednisone. (COG ANBL00P3)

**Purpose:** To determine if intravenous gammaglobulin therapy improves the motor coordination of children diagnosed with neuroblastoma and presenting with opsoclonus-myoclonus-ataxia syndrome as assessed by neurological examination and Vineland Adaptive Behavior Scale. To determine whether intervention with chemotherapy, steroids and IVIG improves the functional outcome of children diagnosed with neuroblastoma and presenting with opsoclonus-myoclonus-ataxia syndrome compared to historical controls.

**Principal Investigator:** Wiley, Joseph M.

**Phase:** III

**For more information, contact:** Entrup, Stephanie

**Telephone Number:** 410-601-8393

**Email** sentrup@lifebridgehealth.org

**Approved Enrollment Number:** 5

**Current Enrollment:** 0